Kari Leigh  Keese net worth and biography

Kari Keese Biography and Net Worth

CFO of Axonics
Ms. Keese leads the company’s finance and accounting functions. She joined Axonics in 2014 and previously served as the company’s Director of Finance and Controller. Prior to Axonics, Ms. Keese was a Controller at Vessix Vascular, Inc., a company that was acquired by Boston Scientific in late 2012. Ms. Keese began her career in public accounting and holds a Bachelor of Arts degree in Business Economics from University of California Santa Barbara and a management certification from UCLA Anderson School of Management.

What is Kari Leigh Keese's net worth?

The estimated net worth of Kari Leigh Keese is at least $2.86 million as of October 2nd, 2024. Ms. Keese owns 40,362 shares of Axonics stock worth more than $2,864,895 as of December 3rd. This net worth approximation does not reflect any other investments that Ms. Keese may own. Additionally, Ms. Keese receives a salary of $1,640,000.00 as CFO at Axonics. Learn More about Kari Leigh Keese's net worth.

How old is Kari Leigh Keese?

Ms. Keese is currently 39 years old. There are 7 older executives and no younger executives at Axonics. The oldest executive at Axonics is Mr. Raymond W. Cohen, Co-Founder, Chief Executive Officer and Director, who is 65 years old. Learn More on Kari Leigh Keese's age.

What is Kari Leigh Keese's salary?

As the CFO of Axonics, Inc., Ms. Keese earns $1,640,000.00 per year. The highest earning executive at Axonics is Mr. Raymond W. Cohen, Co-Founder, Chief Executive Officer and Director, who commands a salary of $1,750,000.00 per year. Learn More on Kari Leigh Keese's salary.

How do I contact Kari Leigh Keese?

The corporate mailing address for Ms. Keese and other Axonics executives is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. Axonics can also be reached via phone at (949) 396-6322 and via email at [email protected]. Learn More on Kari Leigh Keese's contact information.

Has Kari Leigh Keese been buying or selling shares of Axonics?

In the last ninety days, Kari Leigh Keese has sold $205,523.01 in shares of Axonics stock. Most recently, Kari Leigh Keese sold 2,961 shares of the business's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a transaction totalling $205,523.01. Following the completion of the sale, the chief financial officer now directly owns 40,362 shares of the company's stock, valued at $2,801,526.42. Learn More on Kari Leigh Keese's trading history.

Who are Axonics' active insiders?

Axonics' insider roster includes Juliet Bakker (Director), Raymond Cohen (Co-Founder, Chief Executive Officer and Director), Danny Dearen (Insider), Alfred Ford, Jr. (Insider), Kari Keese (CFO), Jane Kiernan (Director), Esteban Lopez (Director), Robert Mcnamara (Director), Karen Noblett (Insider), Rinda Sama (COO), and John Woock (CMO). Learn More on Axonics' active insiders.

Are insiders buying or selling shares of Axonics?

During the last year, insiders at the sold shares 8 times. They sold a total of 92,797 shares worth more than $6,275,226.67. The most recent insider tranaction occured on October, 2nd when CFO Kari Leigh Keese sold 2,961 shares worth more than $205,523.01. Insiders at Axonics own 1.9% of the company. Learn More about insider trades at Axonics.

Information on this page was last updated on 10/2/2024.

Kari Leigh Keese Insider Trading History at Axonics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/2/2024Sell2,961$69.41$205,523.0140,362View SEC Filing Icon  
1/31/2024Sell3,489$67.74$236,344.8643,323View SEC Filing Icon  
See Full Table

Kari Leigh Keese Buying and Selling Activity at Axonics

This chart shows Kari Leigh Keese's buying and selling at Axonics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Axonics Company Overview

Axonics logo
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Read More

Today's Range

Now: $70.98
Low: $70.37
High: $71.05

50 Day Range

MA: $70.32
Low: $69.26
High: $70.98

2 Week Range

Now: $70.98
Low: $55.09
High: $71.05

Volume

4,233,300 shs

Average Volume

713,457 shs

Market Capitalization

$3.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82